Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

ProPAC-COVID
  NCT04322396		 RCTazithromycin plus hydroxychloroquineplaceboCOVID 19 hospitalizedlow
61/56 inconclusive
    Duke university HCQ-AZI
          NCT04335552    		 RCThydroxychloroquine plus macrolidesstandard of careCOVID 19 hospitalizedNA
    		-/- inconclusive
      Arshad (HCQ AZ) OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
      		783/409 suggested
      • suggested 71 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
      Davido
              NCT04453501      		 OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
      		52/40 suggested
      • suggested 55 % decrease in death or transfer to ICU but with a very low degree of certainty due to critical risk of bias
      Lagier OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
      		3119/618 suggested
      • suggested 51 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
      • suggested 70 % decrease in clinical deterioration but with a very low degree of certainty due to critical risk of bias
      • suggested 62 % decrease in hospitalization but with a very low degree of certainty due to critical risk of bias
      Rosenberg OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedserious
      		-/- safety concern
      • safety concern with statistically significant 1.1-fold increase in cardiac arrest
      • statistically significant 1.2-fold increase in arrhythmia but with a low degree of certainty due to high risk of bias
      Sbidian (HCQ plus AZI) OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
      		227/3792 inconclusive

        COVID 19 all comers meta-analysis

        Magagnoli (HC AZ) OBShydroxychloroquine plus macrolidescontrolCOVID 19 all comersserious
        		113/158 inconclusive

          COVID-19 mild to moderate meta-analysis

          Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI
                      NCT04322123          		 RCTazithromycin plus hydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
          		217/227 safety concern
          • inconclusive 1 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 1.2-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 2.5-fold increase in elevated liver enzymes with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 8.8-fold increase in long QT with a moderate degree of certainty due to some concern in risk of bias

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons